Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review)
George Mihai Niţulescu, Horia Păunescu, Sterghios Moschos, et al.
International Journal of Molecular Medicine (2020) Vol. 46, Iss. 2, pp. 467-488
Open Access | Times Cited: 133

Showing 1-25 of 133 citing articles:

COVID-19: Characteristics and Therapeutics
Rameswari Chilamakuri, Saurabh Agarwal
Cells (2021) Vol. 10, Iss. 2, pp. 206-206
Open Access | Times Cited: 259
Azithromycin in the treatment of COVID-19: a review
Daniel Echeverría-Esnal, Clara Martín‐Ontiyuelo, María Eugenia Navarrete-Rouco, et al.
Expert Review of Anti-infective Therapy (2020) Vol. 19, Iss. 2, pp. 147-163
Open Access | Times Cited: 233
Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study
N. Lian, Hong Xie, Rose S.Y. Lin, et al.
Clinical Microbiology and Infection (2020) Vol. 26, Iss. 7, pp. 917-921
Open Access | Times Cited: 221
SARS-CoV-2 spreads through cell-to-cell transmission
Cong Zeng, John P. Evans, Tiffany King, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 119, Iss. 1
Open Access | Times Cited: 201
SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19
Aristides Tsatsakis, Daniela Călina, Luca Falzone, et al.
Food and Chemical Toxicology (2020) Vol. 146, pp. 111769-111769
Open Access | Times Cited: 150
Potential therapeutic options for COVID-19: an update on current evidence
Zahra Niknam, Ameneh Jafari, Ali Golchin, et al.
European journal of medical research (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 136
Unraveling the Possible Routes of SARS-COV-2 Invasion into the Central Nervous System
Maria Lima, Vasileios Siokas, Athina‐Maria Aloizou, et al.
Current Treatment Options in Neurology (2020) Vol. 22, Iss. 11
Open Access | Times Cited: 115
Improved strategies to counter the COVID-19 pandemic: Lockdowns vs. primary and community healthcare
Konstantinos Farsalinos, Konstantinos Poulas, Demetrios Kouretas, et al.
Toxicology Reports (2020) Vol. 8, pp. 1-9
Open Access | Times Cited: 111
[Comment] The COVID‑19 pandemic as a scientific and social challenge in the 21st century
Vassilios Zoumpourlis, Maria Goulielmaki, Emmanouil� Rizos, et al.
Molecular Medicine Reports (2020)
Open Access | Times Cited: 83
Antiviral strategies targeting host factors and mechanisms obliging +ssRNA viral pathogens
Supreeti Mahajan, Shweta Choudhary, Pravindra Kumar, et al.
Bioorganic & Medicinal Chemistry (2021) Vol. 46, pp. 116356-116356
Open Access | Times Cited: 81
Rationale for azithromycin in COVID-19: an overview of existing evidence
Iwein Gyselinck, Wim Janssens, Peter Verhamme, et al.
BMJ Open Respiratory Research (2021) Vol. 8, Iss. 1, pp. e000806-e000806
Open Access | Times Cited: 72
The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm
Maria Kavianpour, Mahshid Saleh, Javad Verdi
Stem Cell Research & Therapy (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 70
Whey proteins and peptides in health-promoting functions – A review
Changhui Zhao, Nan Chen, Tolulope Joshua Ashaolu
International Dairy Journal (2021) Vol. 126, pp. 105269-105269
Closed Access | Times Cited: 63
Metformin prevents cell tumorigenesis through autophagy-related cell death
Mauro De Santi, Giulia Baldelli, Aurora Diotallevi, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 63
[Comment] COVID‑19 vaccine safety
Ronald N. Kostoff, Michael B. Briggs, Alan L. Porter, et al.
International Journal of Molecular Medicine (2020)
Open Access | Times Cited: 63
The obesity paradox: Analysis from the SMAtteo COvid-19 REgistry (SMACORE) cohort
Simona Biscarini, Marta Colaneri, Serena Ludovisi, et al.
Nutrition Metabolism and Cardiovascular Diseases (2020) Vol. 30, Iss. 11, pp. 1920-1925
Open Access | Times Cited: 62
Vaccine- and natural infection-induced mechanisms that could modulate vaccine safety
Ronald N. Kostoff, Darja Kanduc, Alan L. Porter, et al.
Toxicology Reports (2020) Vol. 7, pp. 1448-1458
Open Access | Times Cited: 59
Immune-checkpoint inhibitors from cancer to COVID‑19: A promising avenue for the treatment of patients with COVID‑19 (Review)
Silvia Vivarelli, Luca Falzone, Francesco Torino, et al.
International Journal of Oncology (2020) Vol. 58, Iss. 2, pp. 145-157
Open Access | Times Cited: 58
COVID-19 vaccines: ethical framework concerning human challenge studies
Daniela Călina, Thomas Härtung, Anca Oana Docea, et al.
DARU Journal of Pharmaceutical Sciences (2020) Vol. 28, Iss. 2, pp. 807-812
Open Access | Times Cited: 55
Lactoferrin for the treatment of COVID‑19 (Review)
Yidan Wang, Puxiu Wang, H. J. Wang, et al.
Experimental and Therapeutic Medicine (2020) Vol. 20, Iss. 6, pp. 1-1
Open Access | Times Cited: 52
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) and Spike (S) Proteins Antagonize Host Type I Interferon Response
Qi Zhang, Zhiqiang Chen, Chenxiao Huang, et al.
Frontiers in Cellular and Infection Microbiology (2021) Vol. 11
Open Access | Times Cited: 40
The potential role of resveratrol as supportive antiviral in treating conditions such as COVID-19 – A formulator’s perspective
Roy van Brummelen, Anna C van Brummelen
Biomedicine & Pharmacotherapy (2022) Vol. 148, pp. 112767-112767
Open Access | Times Cited: 28
Microfluidic-based technologies for diagnosis, prevention, and treatment of COVID-19: recent advances and future directions
E. Alperay Tarim, Müge Anıl-İnevi, Ilayda Ozkan, et al.
Biomedical Microdevices (2023) Vol. 25, Iss. 2
Open Access | Times Cited: 16
Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures
Andrés Pizzorno, Olivier Terrier, Claire Nicolas de Lamballerie, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 52
SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches—Insights into Chemical Structure—Biological Activity and Toxicological Screening
Cristina Dehelean, Voichița Elena Lăzureanu, Dorina Coricovac, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 7, pp. 2084-2084
Open Access | Times Cited: 48
Page 1 - Next Page

Scroll to top